UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

_______________________________

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

 

SECURITIES EXCHANGE ACT OF 1934

 

 

 

Date of report (Date of earliest event reported): June 4, 2012

 

Senesco Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware  001-31326  84-1368850 
(State or Other Jurisdiction
of Incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

721 Route 202-206, Suite 130, Bridgewater, NJ   08807 
(Address of Principal Executive Offices) (Zip Code)

   

(908) 864-4444

(Registrant's telephone number,

including area code)

 

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 
 

  

Item 8.01 Other Events.

 

On June 4, 2012, Senesco Technologies, Inc. (“Senesco”) issued a press release announcing the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

 

To date five patients have been enrolled into the study. So far one patient has completed the 6 week dosing schedule. This patient’s disease was considered stable, no disease progression, based on key disease markers including monoclonal protein when evaluated at the end of weeks 3 and 6. Two patients were withdrawn from the study due to disease progression, and two patients are currently being treated. No disease limiting toxicities have been recorded to date.

 

In the study, patients are dosed twice-weekly for 6 weeks followed by an observation period. The first group of patients receives 0.0125 mg/kg by intravenous infusion. At the end of 6 weeks of dosing, safety data for the group will be reviewed before the subsequent group receives a higher dosage. The escalated doses administered to the second to fourth groups will be 0.05, 0.2 and 0.375 mg/kg, respectively.

 

The study is an open-label, multiple-dose, dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein.

 

A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
     
 99.1   Press Release of Senesco Technologies, Inc. dated June 4, 2012.

 

-2-
 

   

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  SENESCO TECHNOLOGIES, INC.
   
   
Dated: June 4, 2012 By: /s/ Leslie J. Browne, Ph.D.
  Name: Leslie J. Browne, Ph.D.
  Title:   President and Chief Executive Officer

 

-3-